
News|Articles|February 6, 2006
New product newswire: February 2, 2006
The FDA gave marketing approval to ZLB Behring, King of Prussia,Pa., for an immunoglobulin (Ig) replacement therapy that can beself-administered by patients at home. Vivaglobin (immune globulinsubcutaneous [human]), indicated for treating patients with primaryimmunodeficiency, delivers antibodies subcutaneously, as analternative to intravenous infusions of immunoglobulin, to fightlife-threatening infections. The firm can be reached at (610)878-4000.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Targeted Coordination Is Crucial in Boosting Pneumococcal Vaccine Coverage
2
CoronaVac Improves Outcomes of COVID-19 for Patients With Schizophrenia
3
Wegovy Pill Receives FDA Approval as First Oral GLP-1 for Weight-Loss
4
Reducing HIV Stigma Can Improve Patient Care, Provider Connectivity
5
















































































































